Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

Abstract

Pneumonitis is a complication of high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) regimens containing BCNU. Our goal was to define the incidence and risk factors for pneumonitis in patients with lymphoma receiving a uniform conditioning regimen in the modern era. We studied 222 patients who received HDC-ASCT using cyclophosphamide, BCNU and VP-16 (CBV). Pneumonitis incidence was 22%, with 19% receiving systemic corticosteroid treatment and 8% requiring inpatient hospitalization for pneumonitis. Three patients died secondary to pneumonitis-related complications. The following variables were independently associated with pneumonitis: prior mediastinal radiation (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.3–18.9, p = 0.0005), total BCNU dose above 1000 mg (OR 3.4, 95% CI 1.3–8.7, p = 0.012) and age less than 54 (OR 3.0, 95% CI 1.4–6.5, p = 0.0037). Increased vigilance for symptoms of pneumonitis is warranted for patients with prior mediastinal radiation and for younger patients, and dose reduction may be considered for patients who would receive greater than 1000 mg of BCNU.

Keywords::

• Transplant toxicity
• clinical results
• lymphoma and Hodgkin disease

Acknowledgements

The authors thank Joseph Antin and Janet Murphy for helpful discussions.

Y.-B.C. is a recipient of a career development award from the Leukemia & Lymphoma Society. Additional support provided was by NIH T32 CA071345 (A.A.L.).

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at http://www.informahealthcare.com/lal.